作者
Adrian G. Sacher,M.R. Patel,W.H. Miller,J. Desai,E. Garralda,S. Bowyer,T.W. Kim,M. De Miguel,A. Falcon,M.G. Krebs,J. Lee,M. Cheng,S.-W. Han,E. Shacham-Shmueli,M. Forster,G. Jerusalem,E. Massarelli,Luis Paz-Ares Rodríguez,H. Prenen,I. Walpole,K. Arbour,Y. Choi,N.V. Dharia,M. Lin,S. Mandlekar,S. Royer Joo,Zhe Shi,J. Schutzman,P. LoRusso
摘要
KRAS G12C is one of the most common oncogenic mutations in NSCLC. GDC-6036 is an oral, highly potent, and selective KRAS G12C inhibitor with robust tumor growth inhibition in multiple pre-clinical models. An open-label, Phase I dose-escalation/expansion study of GDC-6036 as monotherapy and in combination with other anticancer therapies is underway for patients (pts) with locally advanced or metastatic solid tumors harboring a KRAS G12C mutation. Data from GDC-6036 monotherapy in pts with NSCLC are presented herein.